145 related articles for article (PubMed ID: 36880872)
1. Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection.
Peraza MA; Hurst S; Huang W; Buetow BS; Lickteig AJ; Lavach JD; Frost DF; Collins ME; Sellers RS; Matsumoto Smith D
J Ocul Pharmacol Ther; 2023 Apr; 39(3):215-224. PubMed ID: 36880872
[No Abstract] [Full Text] [Related]
2. Initial Experience With Biosimilar Bevacizumab-bvzr For Intravitreal Use in Children: A Case Series and Literature Review.
Jung EE; Lee TC; Nagiel A
Ophthalmic Surg Lasers Imaging Retina; 2023 Feb; 54(2):84-88. PubMed ID: 36780635
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys.
Yu DA; You M; Ji WW; Lu Y; Liu B; Yan SS
Toxicol Lett; 2018 Aug; 292():73-77. PubMed ID: 29709424
[TBL] [Abstract][Full Text] [Related]
4. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
5. Non-clinical pharmacology and toxicology studies of bevacizumab biosimilar LY01008.
Guangying D; Shuzhi M; Xiaoyin Z; Pengfei Y; Xin Y; Liang Y; Xin S; Baiping S; Changlin D; Hongbo W; Jingwei T
Eur J Pharmacol; 2022 Dec; 936():175383. PubMed ID: 36347321
[TBL] [Abstract][Full Text] [Related]
6. Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice.
Yang J; Kelton JM; Thompson J; Alvir JMJ; Maculaitis MC; Shelbaya A
Am J Manag Care; 2022 Apr; 28(4):160-166. PubMed ID: 35420744
[TBL] [Abstract][Full Text] [Related]
7. Penetration of bevacizumab through the retina after intravitreal injection in the monkey.
Heiduschka P; Fietz H; Hofmeister S; Schultheiss S; Mack AF; Peters S; Ziemssen F; Niggemann B; Julien S; Bartz-Schmidt KU; Schraermeyer U;
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2814-23. PubMed ID: 17525217
[TBL] [Abstract][Full Text] [Related]
8. Effect of the Honan intraocular pressure reducer to prevent vitreous reflux after intravitreal bevacizumab injection.
Hong SW; Jee D
Eur J Ophthalmol; 2012; 22(4):615-9. PubMed ID: 22562298
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravitreal injection of high-dose bevacizumab in monkey eyes.
Sakurai K; Akiyama H; Shimoda Y; Yoshida I; Kurabayashi M; Kishi S
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4905-16. PubMed ID: 19407010
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
[TBL] [Abstract][Full Text] [Related]
12. Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes.
Xu W; Wang H; Wang F; Jiang Y; Zhang X; Wang W; Qian J; Xu X; Sun X
Can J Ophthalmol; 2010 Aug; 45(4):386-92. PubMed ID: 20648082
[TBL] [Abstract][Full Text] [Related]
13. Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes.
Schraermeyer U; Julien S
Expert Opin Biol Ther; 2013 Feb; 13(2):157-67. PubMed ID: 23190450
[TBL] [Abstract][Full Text] [Related]
14. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema.
Daull P; Paterson CA; Kuppermann BD; Garrigue JS
J Ocul Pharmacol Ther; 2013 Mar; 29(2):258-69. PubMed ID: 23331052
[TBL] [Abstract][Full Text] [Related]
15. Ocular and systemic pharmacokinetics of BI-X, a nanobody targeting VEGF and Ang-2, after intravitreal dosing in cynomolgus monkeys - Evidence for half-life extension by albumin.
Fuchs H; Chen LZ; Low S; Yu H
Exp Eye Res; 2021 Apr; 205():108486. PubMed ID: 33571529
[TBL] [Abstract][Full Text] [Related]
16. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.
Aisenbrey S; Ziemssen F; Völker M; Gelisken F; Szurman P; Jaissle G; Grisanti S; Bartz-Schmidt KU
Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):941-8. PubMed ID: 17186262
[TBL] [Abstract][Full Text] [Related]
19. Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics.
Bantseev V; Erickson R; Leipold D; Amaya C; Miller PE; Booler H; Thackaberry EA
J Ocul Pharmacol Ther; 2018; 34(1-2):204-213. PubMed ID: 29148965
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
Miyake T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ogasawara K; Ohji M
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
